BHVN

Biohaven is a clinical-stage biopharma that, in its own words, has "not generated any revenue from product sales and we do not expect to generate any revenue from the sale of products in the near future." There is nothing to value on a cash-flow or earnings basis: FY2025 net income was -$739M, operating income -$745M, diluted EPS -$6.86, and operating cash flow -$609M. The entire ~$2.2B market cap (150M shares × $14.95) is option value on a pipeline now narrowed, in a Q4-2025 "strategic reprioritization," to three buckets — Kv7 for epilepsy, MoDE/TRAP protein degradation, and a myostatin-activin agent for obesity/neuromuscular disease. R&D alone ran $635M for the year. This is a story stock, not a fundamentals stock, and the rubric is clear: unprofitable, weak balance sheet, unknowable binary risk — not investable on quality.

The balance sheet is the disqualifier. Stockholders' equity collapsed 87.7% to $52.1M while total liabilities more than doubled (+108.4%) to $399M, pushing liabilities/equity to 7.67x and ROE to -1418.8% — a near-insolvent equity cushion against a company that burns roughly $150M a quarter. Cash of $230M (flattered +132% by the April 2025 Oberland note proceeds) covers well under half a year of that burn. Funding has come at shareholders' direct expense: shares outstanding jumped 47.4% YoY, and the Note Purchase Agreement layers on senior secured, royalty-bearing debt — 6.25% of troriluzole global net sales, with a punitive step-up if the 2030 Test Date Condition isn't met. Equity holders sit behind that paper.